Amy G Shah1, Paula G Smith, Richard K Sterling. 1. Divisions of Gastroenterology, Hepatology and Nutrition Infectious Diseases, Virginia Commonwealth University Health System, Richmond, VA, USA.
Abstract
BACKGROUND AND AIMS: Liver biopsy is standard for assessment of disease severity in patients with chronic HCV. However, associated risks have led to the development of simple non-invasive models. However, their utility in those with normal ALT is unknown. METHODS: FIB-4 and APRI were calculated for patients with HIV-HCV coinfection undergoing biopsy. The performance of each model and AUROC for predicting significant fibrosis (Ishak 4-6) were determined for the entire cohort and stratified by elevated (≥60 U/l in men and ≥40 U/l in women) and normal ALT. RESULTS: Two-hundred and ninety-five liver biopsies from 237 patients were included. Elevated ALT was observed in 55, and 15% had significant fibrosis. The AUROC curve for patients with elevated ALT was 0.8 for FIB-4 and 0.76 for APRI, compared with 0.90 for the FIB-4 and 0.85-0.95 for the APRI in those with normal ALT. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FIB-4 were 1.0, 0.91, 0.50, and 1.0 for patients with normal ALT; the values were 0.67, 0.99, 0.67, and 0.99 for APRI. CONCLUSIONS: Both FIB-4 and APRI are useful for highly accurate identification of those without advanced fibrosis. However, because they have poor positive predictive value, liver biopsy will continue to be used for assessment of patients with coinfection.
BACKGROUND AND AIMS: Liver biopsy is standard for assessment of disease severity in patients with chronic HCV. However, associated risks have led to the development of simple non-invasive models. However, their utility in those with normal ALT is unknown. METHODS: FIB-4 and APRI were calculated for patients with HIV-HCV coinfection undergoing biopsy. The performance of each model and AUROC for predicting significant fibrosis (Ishak 4-6) were determined for the entire cohort and stratified by elevated (≥60 U/l in men and ≥40 U/l in women) and normal ALT. RESULTS: Two-hundred and ninety-five liver biopsies from 237 patients were included. Elevated ALT was observed in 55, and 15% had significant fibrosis. The AUROC curve for patients with elevated ALT was 0.8 for FIB-4 and 0.76 for APRI, compared with 0.90 for the FIB-4 and 0.85-0.95 for the APRI in those with normal ALT. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FIB-4 were 1.0, 0.91, 0.50, and 1.0 for patients with normal ALT; the values were 0.67, 0.99, 0.67, and 0.99 for APRI. CONCLUSIONS: Both FIB-4 and APRI are useful for highly accurate identification of those without advanced fibrosis. However, because they have poor positive predictive value, liver biopsy will continue to be used for assessment of patients with coinfection.
Authors: Richard K Sterling; Jacob A Wegelin; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Puneet Puri; Mitchell L Shiffman; Melissa A Contos; A Scott Mills; Arun J Sanyal Journal: Clin Gastroenterol Hepatol Date: 2010-08-20 Impact factor: 11.382
Authors: M Persico; E Persico; R Suozzo; S Conte; M De Seta; L Coppola; B Palmentieri; F C Sasso; R Torella Journal: Gastroenterology Date: 2000-04 Impact factor: 22.682
Authors: Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: Montserrat Laguno; Javier Murillas; José Luis Blanco; Esteban Martínez; Rosa Miquel; José M Sánchez-Tapias; Xavier Bargallo; Angeles García-Criado; Elisa de Lazzari; María Larrousse; Agathe León; Montserrat Loncá; Ana Milinkovic; Josep M Gatell; Josep Mallolas Journal: AIDS Date: 2004-09-03 Impact factor: 4.177
Authors: Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Klaus Langohr; Arantza Sanvisens; Daniel Fuster; Jordi Tor; Isabel Serra; Celestino Rey-Joly; Inmaculada Rivas; Roberto Muga Journal: Open AIDS J Date: 2008-11-20
Authors: Peter Ferenci; Rodrigo Aires; Kimberly L Beavers; Manuela Curescu; Paulo R Abrão Ferreira; Michael Gschwantler; Stefan Ion; Dominique Larrey; Mojca Maticic; Massimo Puoti; János Schuller; Istvan Tornai; Anna Tusnádi; Diethelm Messinger; Fernando Tatsch; Andrzej Horban Journal: Hepatol Int Date: 2013-11-22 Impact factor: 6.047
Authors: M Shadab Siddiqui; Kavish R Patidar; Sherry Boyett; Paula G Smith; Arun J Sanyal; Richard K Sterling Journal: Clin Gastroenterol Hepatol Date: 2014-07-05 Impact factor: 11.382
Authors: Kali Zhou; Fengyu Hu; Charles Wang; Min Xu; Yun Lan; Jamie P Morano; Stanley M Lemon; Joseph D Tucker; Weiping Cai Journal: BMC Infect Dis Date: 2015-09-30 Impact factor: 3.090
Authors: Giada Sebastiani; Kathleen C Rollet-Kurhajec; Costa Pexos; Norbert Gilmore; Marina B Klein Journal: Open Forum Infect Dis Date: 2015-02-23 Impact factor: 3.835
Authors: Erin M Kelly; Jennifer L Dodge; Peter Bacchetti; Monika Sarkar; Audrey L French; Phyllis C Tien; Marshall J Glesby; Elizabeth T Golub; Michael Augenbraun; Michael Plankey; Marion G Peters Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079